Amgen Set to Present at Evercore HealthCONx Conference
Amgen (NASDAQ: AMGN) is poised to showcase its cutting-edge advancements at the upcoming Evercore HealthCONx Conference. This esteemed event is scheduled to feature key experts from Amgen, including Peter Griffith, the executive vice president and chief financial officer. Alongside him, the conference will have contributions from Jay Bradner, executive vice president of Research and Development and chief scientific officer, and Susan Sweeney, executive vice president overseeing Obesity and Related Conditions.
Details of the Conference Engagement
The presentation is set for 10:00 a.m. ET, marking a significant opportunity for Amgen to connect with media, investors, and the public. The discussions will encompass various innovative strategies that Amgen employs to tackle some of the toughest diseases, ensuring a comprehensive understanding of their mission and progress in biotechnology.
Webcast Information
The conference will be broadcasted online, ensuring that those unable to attend in person can still participate. Details regarding the webcast are accessible on Amgen's Investor Relations section of their website. Notably, the recorded session will remain available for at least 90 days, giving stakeholders the chance to revisit these vital discussions on Amgen's initiatives and advancements.
About Amgen: A Leader in Biotechnology
For over four decades, Amgen has been at the forefront of biotechnology. The company specializes in discovering and developing innovative medicines with the intent to help patients facing significant health challenges. With a commitment to utilizing technology and human genetic insights, Amgen is continually pushing the boundaries of what is achievable in medicine.
Recognition and Accolades
This year, Amgen has received notable accolades, featuring on lists such as "World's Most Innovative Companies" and "America's Best Large Employers." Such recognitions affirm Amgen's dedication to not only fostering innovation but also maintaining a workplace culture where employees feel valued and supported.
Investor Relations and Future Directions
As part of the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen's standing reflects its immense value in the biotechnology industry. The company is continually expanding its pipeline, focusing on treating a range of conditions from cancer to inflammatory diseases. Their recent acquisition strategies and advancements in research exemplify Amgen's proactive approach in the competitive healthcare landscape.
Communication and Contact
For further information on Amgen’s corporate strategy and outlet for investor inquiries, stakeholders can reach out directly to their media relations team. Highlighting transparency and open communication has always been integral to Amgen's ethos, allowing investors and the public to remain informed about their strategies and outcomes.
Frequently Asked Questions
1. What is the main focus of Amgen's presentation at the conference?
Amgen will discuss innovative approaches in biotechnology and advancements in treating serious health conditions.
2. Who are the key speakers representing Amgen?
Executives Peter Griffith, Jay Bradner, and Susan Sweeney will participate in the discussions during the event.
3. How can stakeholders access the conference presentation?
The conference will be live-streamed, and the recording will be available on Amgen's Investor Relations website for 90 days post-event.
4. What awards has Amgen received recently?
Amgen was recognized as one of the "World's Most Innovative Companies" and "America's Best Large Employers," highlighting its commitment to innovation and employee satisfaction.
5. How does Amgen plan to continue its innovation in healthcare?
Amgen is focused on expanding its drug pipeline and utilizing advanced research to stay ahead in the biotechnology sector while ensuring patient welfare is prioritized.
